Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance

SIMPLE SUMMARY: Melanoma is a highly metastatic and therapy-resistant cancer and is therefore associated with low survival rates of patients. In melanoma, the inactivation of the wild-type form of the p53 tumour suppressor protein is a frequent event, mainly through interactions with MDM2 and MDMX....

Descripción completa

Detalles Bibliográficos
Autores principales: Loureiro, Joana B., Raimundo, Liliana, Calheiros, Juliana, Carvalho, Carla, Barcherini, Valentina, Lima, Nuno R., Gomes, Célia, Almeida, Maria Inês, Alves, Marco G., Costa, José Luís, Santos, Maria M. M., Saraiva, Lucília
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037490/
https://www.ncbi.nlm.nih.gov/pubmed/33916029
http://dx.doi.org/10.3390/cancers13071648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037490/
https://www.ncbi.nlm.nih.gov/pubmed/33916029
http://dx.doi.org/10.3390/cancers13071648

Ejemplares similares